Welcome to our dedicated page for Establishment Labs Hldgs news (Ticker: ESTA), a resource for investors and traders seeking the latest updates and insights on Establishment Labs Hldgs stock.
News and updates for Establishment Labs Holdings Inc. (NASDAQ: ESTA) center on its role as a global medical device company dedicated to women’s health, particularly in breast aesthetics and reconstruction. Company announcements frequently highlight developments in its Motiva breast implant portfolio, minimally invasive platforms, and reconstruction technologies, as well as financial performance and corporate events.
Investors and clinicians following ESTA news can expect regular coverage of quarterly and annual financial results, including revenue trends, margins, and cash position as disclosed in earnings releases and accompanying conference calls. The company also reports on financing arrangements, such as amendments to its credit agreement and access to additional term loan tranches, through Form 8-K filings and press releases.
Product and clinical news is a recurring theme. Establishment Labs issues updates on regulatory milestones, such as FDA submissions and indications for Motiva implants in breast augmentation and reconstruction. It also shares outcomes from clinical studies, including prospective trials of Mia Femtech, and annual Post-Market Surveillance reports summarizing real-world performance data for Motiva implants across global markets.
Conference participation and investor outreach are another focus of ESTA news. The company announces presentations at major healthcare investment conferences, including events hosted by J.P. Morgan and Jefferies, where its leadership discusses strategy, product platforms, and market opportunities. For users tracking the ESTA stock, this news feed provides a consolidated view of financial disclosures, regulatory updates, clinical evidence, and corporate presentations related to Establishment Labs.
Establishment Labs Holdings Inc. (NASDAQ: ESTA), a leader in women's health technology, has secured Hani Zeini for a multiyear advisory role as it prepares for its US market launch. Zeini, with over 30 years in aesthetics, previously founded Sientra. His expertise will drive the company's strategy to introduce innovative breast aesthetics solutions, including the Motiva Implant product suite. With 2.0 million implants distributed globally, Establishment Labs is on track to enhance its market presence.
Establishment Labs Holdings Inc. (Nasdaq: ESTA) reported second-quarter revenues of $41.2 million, a 28.7% increase year-over-year, marking a new record. Adjusted for currency fluctuations, growth would have been 33.3%. Gross profit was 66.7% of revenue, slightly down from 67.1% in 2021. Operating expenses rose to $37.9 million, a 45% increase compared to the previous year. The company maintains its 2022 revenue guidance of $155 million to $165 million. Cash balance stood at $91.3 million as of June 30, 2022, bolstered by a new $225 million credit facility.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) has announced the completion of patient enrollment in the Motiva US IDE clinical study, which involved 827 patients across 32 centers in the US, Germany, and Sweden. The study aims to evaluate the safety and effectiveness of Motiva breast implants in various procedures. The company plans to file its PMA submission to the FDA in Q4 2023, building on this significant milestone, especially amid the challenges posed by the pandemic. The Motiva implants have been positively received in reconstructive surgery.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) will announce its financial results for Q2 2022 on August 8, 2022, after market close. A conference call will be held at 4:30 PM ET to discuss these results. The company specializes in women's health, focusing on breast aesthetics and reconstruction, and has delivered over 2 million Motiva Implants since its launch in 2010. Their implants are known for advanced features that aim to enhance aesthetic and clinical outcomes.
Summary not available.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) announced that its CEO, Juan José Chacón-Quirós, and CFO, Raj Denhoy will present at the Jefferies Healthcare Conference on June 8, 2022, at 10:30 am Eastern Time. A live webcast will be available on the company's investor relations website, with an archived version accessible afterward. Founded to enhance women's health, Establishment Labs specializes in breast aesthetics and reconstruction, offering innovative products like Motiva Implants®, with 2 million units distributed globally since 2010.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) reported strong first-quarter 2022 results, with revenue of $38.5 million, a 26.8% year-over-year increase. Despite reaching a record high in sales, gross profit margin declined to 64.8% due to higher inventory reserves. Operating expenses surged 37.5% to $30.5 million, contributing to a net loss of $5.6 million, up from $2.1 million the previous year. The company maintains its revenue guidance of $155 million to $165 million for 2022, reflecting an ambitious growth outlook.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) will announce its financial results for Q1 2022 on May 9, 2022, after market close. A conference call to discuss these results will follow at 4:30 pm ET. Established in 2010, Establishment Labs focuses on improving women’s health, particularly in breast aesthetics and reconstruction, offering Motiva Implants® and related products. More than 2 million Motiva Implants® have been delivered globally. For further details, visit www.establishmentlabs.com.
Establishment Labs has secured a senior secured term loan facility of up to $225 million from Oaktree Capital Management, with an initial draw of $150 million. The funding aims to enhance the company's cash flow and support its expansion in the breast aesthetics market, including upcoming product launches in the United States and China. The loan matures in five years with an interest rate starting at 9.00% per annum, reducing to 8.25% upon meeting certain milestones.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) presented interim data from its Motiva US IDE Study at The Aesthetic Meeting 2022 in San Diego. This includes two-year follow-up data for 451 primary augmentation patients, showing a 94.9% compliance rate. Notable findings include low complication rates, with capsular contracture at 0.5% and rupture at 0.3%. Dr. Caroline Glicksman emphasized the significance of these preliminary results, contributing to the clinical understanding of Motiva Implants. The Motiva device remains investigational and not yet FDA-approved for commercial use in the U.S.